Stability of IgG isotypes in serum

References

• Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol 2007; 25:1369 - 1372
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2010. MAbs 2010; 2:84 - 100
   PubMed Web of Science ®Google Scholar
• Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci 2009; 100:1566 - 1572
   PubMed Web of Science ®Google Scholar
• Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343 - 357
   PubMed Web of Science ®Google Scholar
• Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073 - 1078
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004; 3:711 - 715
   PubMed Web of Science ®Google Scholar
• Pavlou AK, Belsey MJ. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 2005; 59:389 - 396
   PubMed Web of Science ®Google Scholar
• Scott C. The problem with potency. Nature Biotechnol 2005; 23:1037 - 1039
   PubMed Web of Science ®Google Scholar
• Porter R. Chemical structure of γ-globulins and antibodies. Br Med Bull 1 1963; 19:197 - 201
   PubMed Web of Science ®Google Scholar
• Edelman GM, Poulik MD. Studies on structural units of the gamma-globulins. J Exp Med 1961; 113:861 - 884
   PubMed Web of Science ®Google Scholar
• Edelman GM, Benacerraf B, Ovary Z, Poulik MD. Structural differences among antibodies of different specificities. Proc Natl Acad Sci USA 1961; 47:1751 - 1758
   PubMed Web of Science ®Google Scholar
• Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 2004; 4:89 - 99
   PubMed Web of Science ®Google Scholar
• Barclay AN. Membrane proteins with immunoglobulin-like domains—a master superfamily of interaction molecules. Semin Immunol 2003; 15:215 - 223
   PubMed Web of Science ®Google Scholar
• Jefferis R, Lefranc M. Human immunoglobulin allotypes. MAbs 2009; 1:1 - 7
   Google Scholar
• Pink JR, Milstein C. Inter heavy-light chain disulphide bridge in immune globulins. Nature 1967; 214:92 - 94
   PubMed Web of Science ®Google Scholar
• Milstein C, Pink JR. Structure and evolution of immunoglobulins. Prog Biophys Mol Biol 1970; 21:209 - 263
   PubMedGoogle Scholar
• Milstein C, Frangione B. Disulphide bridges of the heavy chain of human immunoglobulin G2. Biochem J 1971; 121:217 - 225
   PubMed Web of Science ®Google Scholar
• Frangione B, Milstein C, Pink JR. Structural studies of immunoglobulin G. Nature 1969; 221:145 - 148
   PubMed Web of Science ®Google Scholar
• Frangione B, Milstein C, Franklin EC. Intrachain disulphide bridges in immunoglobulin G heavy chains. The Fc fragment. Biochem J 1968; 106:15 - 21
   PubMed Web of Science ®Google Scholar
• Frangione B, Milstein C, Franklin EC. Chemical typing of immunoglobulins. Nature 1969; 221:149 - 151
   PubMed Web of Science ®Google Scholar
• Frangione B, Milstein C. Variations in the S-S bridges of immunoglobins G: interchain disulfide bridges of gamma G3 myeloma proteins. J Mol Biol 1968; 33:893 - 906
   PubMedGoogle Scholar
• De Preval C, Pink JR, Milstein C. Variability of interchain binding of immunoglobulins. Interchain bridges of mouse IgG2a and IgG2b. Nature 1970; 228:930 - 932
   PubMed Web of Science ®Google Scholar
• Issaq HJ, Xiao Z, Veenstra TD. Serum and plasma proteomics. Chem Rev 2007; 107:3601 - 3620
   PubMed Web of Science ®Google Scholar
• Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004; 3:311 - 326
   PubMed Web of Science ®Google Scholar
• Anderson NL, Anderson NG. The human plasma proteome: history, character and diagnostic prospects. Mol Cell Proteomics 2002; 1:845 - 867
   PubMed Web of Science ®Google Scholar
• Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, Miller SS, et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003; 3:1345 - 1364
   PubMed Web of Science ®Google Scholar
• Michel PE, Crettaz D, Morier P, Heller M, Gallot D, Tissot JD, et al. Proteome analysis of human plasma and amniotic fluid by Off-Gel isoelectric focusing followed by nano-LC-MS/MS. Electrophoresis 2006; 27:1169 - 1181
   PubMed Web of Science ®Google Scholar
• Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. Serum proteomics profiling—a young technology begins to mature. Nat Biotechnol 2005; 23:291 - 292
   PubMed Web of Science ®Google Scholar
• Demeule B, Shire SJ, Liu J. A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: a study by analytical ultracentrifugation. Anal Biochem 2009; 388:279 - 287
   PubMed Web of Science ®Google Scholar
• Summa D, Spiga O, Bernini A, Venditti V, Priora R, Frosali S, et al. Protein-thiol substitution or protein dethiolation by thiol/disulfide exchange reactions: the albumin model. Proteins 2007; 69:369 - 378
   PubMed Web of Science ®Google Scholar
• Soriani M, Pietraforte D, Minetti M. Antioxidant potential of anaerobic human plasma: role of serum albumin and thiols as scavengers of carbon radicals. Arch Biochem Biophys 1994; 312:180 - 188
   PubMed Web of Science ®Google Scholar
• Mills BJ, Weiss MM, Lang CA, Liu MC, Ziegler C. Blood glutathione and cysteine changes in cardiovascular disease. J Lab Clin Med 2000; 135:396 - 401
   PubMedGoogle Scholar
• Hildebrandt W, Kinscherf R, Hauer K, Holm E, Droge W. Plasma cystine concentration and redox state in aging and physical exercise. Mech Ageing Dev 2002; 123:1269 - 1281
   PubMed Web of Science ®Google Scholar
• Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 1993; 39:263 - 271
   PubMed Web of Science ®Google Scholar
• Di Giuseppe D, Di Simplicio P, Capecchi PL, Lazzerini PE, Pasini FL. Alteration in the redox state of plasma in heart-transplant patients with moderate hyperhomocysteinemia. J Lab Clin Med 2003; 142:21 - 28
   PubMedGoogle Scholar
• Andersson A, Isaksson A, Brattstrom L, Hultberg B. Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolumn derivatization. Clin Chem 1993; 39:1590 - 1597
   PubMed Web of Science ®Google Scholar
• Weintraub SJ, Manson SR. Asparagine deamidation: a regulatory hourglass. Mech Ageing Dev 2004; 125:255 - 257
   PubMed Web of Science ®Google Scholar
• Cournoyer JJ, O’Connor PB. Whitelegge J. Analysis of Deamidation in Proteins. Protein Mass Spectrometry 2008; 52:Amsterdam Elsevier 375 - 410
   Google Scholar
• Pan H, Chen K, Chu L, Kinderman F, Apostol I, Huang G. Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci 2009; 18:424 - 433
   PubMed Web of Science ®Google Scholar
• Liu YD, van Enk JZ, Flynn GC. Human antibody Fc deamidation in vivo. Biologicals 2009; 37:313 - 322
   PubMed Web of Science ®Google Scholar
• Wang L, Amphlett G, Lambert JM, Blattler W, Zhang W. Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry. Pharm Res 2005; 22:1338 - 1349
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci 2008; 97:2426 - 2447
   PubMed Web of Science ®Google Scholar
• Chelius D, Rehder DS, Bondarenko PV. Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. Anal Chem 2005; 77:6004 - 6011
   PubMed Web of Science ®Google Scholar
• Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem 2005; 77:1432 - 1439
   PubMed Web of Science ®Google Scholar
• Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 2001; 752:233 - 245
   PubMed Web of Science ®Google Scholar
• Doyle HA, Zhou J, Wolff MJ, Harvey BP, Roman RM, Gee RJ, et al. Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity. J Biol Chem 2006; 281:32676 - 32683
   PubMed Web of Science ®Google Scholar
• Doyle HA, Gee RJ, Mamula MJ. Altered immunogenicity of isoaspartate containing proteins. Autoimmunity 2007; 40:131 - 137
   PubMed Web of Science ®Google Scholar
• Yan B, Steen S, Hambly D, Valliere-Douglass J, Vanden Bos T, Smallwood S, et al. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci 2009; 98:3509 - 3521
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Sun J. Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 837:35 - 43
   PubMed Web of Science ®Google Scholar
• Li N, Kessler K, Bass L, Zeng D. Evaluation of the iCE280 Analyzer as a potential high-throughput tool for formulation development. J Pharm Biomed Anal 2007; 43:963 - 972
   PubMed Web of Science ®Google Scholar
• Hambly DM, Banks DD, Scavezze JL, Siska CC, Gadgil HS. Detection and quantitation of IgG 1 hinge aspartate isomerization: a rapid degradation in stressed stability studies. Anal Chem 2009; 81:7454 - 7459
   PubMed Web of Science ®Google Scholar
• Robinson NE, Robinson AB. Molecular clocks. Proc Natl Acad Sci USA 2001; 98:944 - 949
   PubMed Web of Science ®Google Scholar
• Robinson NE, Robinson AB. Deamidation of human proteins. Proc Natl Acad Sci USA 2001; 98:12409 - 12413
   PubMed Web of Science ®Google Scholar
• Robinson NE. Protein deamidation. Proc Natl Acad Sci USA 2002; 99:5283 - 5288
   PubMed Web of Science ®Google Scholar
• Robinson AB, McKerrow JH, Cary P. Controlled deamidation of peptides and proteins: an experimental hazard and a possible biological timer. Proc Natl Acad Sci USA 1970; 66:753 - 757
   PubMed Web of Science ®Google Scholar
• Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, et al. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 2008; 47:5088 - 5100
   PubMed Web of Science ®Google Scholar
• Kroon DJ, Baldwin-Ferro A, Lalan P. Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. Pharm Res 1992; 9:1386 - 1393
   PubMed Web of Science ®Google Scholar
• Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, McKelvey T, et al. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol 2009; 46:1878 - 1882
   PubMed Web of Science ®Google Scholar
• Lam XM, Yang JY, Cleland JL. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 1997; 86:1250 - 1255
   PubMed Web of Science ®Google Scholar
• Chumsae C, Gaza-Bulseco G, Sun J, Liu H. Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 850:285 - 294
   PubMed Web of Science ®Google Scholar
• Teh LC, Murphy LJ, Huq NL, Surus AS, Friesen HG, Lazarus L, et al. Methionine oxidation in human growth hormone and human chorionic somatomammotropin. Effects on receptor binding and biological activities. J Biol Chem 1987; 262:6472 - 6477
   PubMed Web of Science ®Google Scholar
• Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004; 21:897 - 903
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII and FcRn and design of IgG1 variants with improved binding to the FcgammaR. J Biol Chem 2001; 276:6591 - 6604
   PubMed Web of Science ®Google Scholar
• Martin WL, West AP Jr, Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001; 7:867 - 877
   PubMed Web of Science ®Google Scholar
• Medesan C, Matesoi D, Radu C, Ghetie V, Ward ES. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol 1997; 158:2211 - 2217
   PubMed Web of Science ®Google Scholar
• Kim JK, Tsen MF, Ghetie V, Ward ES. Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur J Immunol 1994; 24:2429 - 2434
   Google Scholar
• Ghetie V, Ward ES. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 1997; 18:592 - 598
   PubMed Web of Science ®Google Scholar
• Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function and expression. Physiol Rev 1995; 75:591 - 609
   PubMed Web of Science ®Google Scholar
• Stahl PD. The mannose receptor and other macrophage lectins. Curr Opin Immunol 1992; 4:49 - 52
   PubMed Web of Science ®Google Scholar
• Pontow SE, Kery V, Stahl PD. Mannose receptor. Int Rev Cytol 1992; 137:221 - 244
   Google Scholar
• Lee SJ, Evers S, Roeder D, Parlow AF, Risteli J, Risteli L, et al. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 2002; 295:1898 - 1901
   PubMed Web of Science ®Google Scholar
• Bridges K, Harford J, Ashwell G, Klausner RD. Fate of receptor and ligand during endocytosis of asialoglycoproteins by isolated hepatocytes. Proc Natl Acad Sci USA 1982; 79:350 - 354
   PubMed Web of Science ®Google Scholar
• Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982; 51:531 - 554
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation of natural and recombinant antibody molecules. Adv Exp Med Biol 2005; 564:143 - 148
   PubMed Web of Science ®Google Scholar
• Chen X, Liu YD, Flynn GC. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 2009; 19:240 - 249
   PubMed Web of Science ®Google Scholar
• Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 2008; 99:652 - 665
   PubMed Web of Science ®Google Scholar
• Wright A, Morrison SL. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 1994; 180:1087 - 1096
   PubMed Web of Science ®Google Scholar
• Newkirk MM, Novick J, Stevenson MM, Fournier MJ, Apostolakos P. Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice. Clin Exp Immunol 1996; 106:259 - 264
   PubMed Web of Science ®Google Scholar
• Millward TA, Heitzmann M, Bill K, Langle U, Schumacher P, Forrer K. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals 2008; 36:41 - 47
   PubMed Web of Science ®Google Scholar
• Keck R, Nayak N, Lerner L, Raju S, Ma S, Schreitmueller T, et al. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologicals 2008; 36:49 - 60
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid and complex types. Glycobiology 2007; 17:104 - 118
   PubMed Web of Science ®Google Scholar
• Huang L, Biolsi S, Bales KR, Kuchibhotla U. Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. Anal Biochem 2006; 349:197 - 207
   PubMed Web of Science ®Google Scholar
• Chaderjian WB, Chin ET, Harris RJ, Etcheverry TM. Effect of copper sulfate on performance of a serum-free CHO cell culture process and the level of free thiol in the recombinant antibody expressed. Biotechnol Prog 2005; 21:550 - 553
   PubMed Web of Science ®Google Scholar
• Banks DD, Gadgil HS, Pipes GD, Bondarenko PV, Hobbs V, Scavezze JL, et al. Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recombinant monoclonal IgG1 antibody improves homogeneity, stability and biological activity. J Pharm Sci 2008; 97:775 - 790
   PubMed Web of Science ®Google Scholar
• van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554 - 1557
   PubMed Web of Science ®Google Scholar
• Liu YD, Chen X, Enk JZ, Plant M, Dillon TM, Flynn GC. Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 2008; 283:29266 - 29272
   PubMed Web of Science ®Google Scholar
• van der Zee JS, van Swieten P, Aalberse RC. Serologic aspects of IgG4 antibodies II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol 1986; 137:3566 - 3571
   PubMed Web of Science ®Google Scholar
• Schuurman J, Van Ree R, Perdok GJ, Van Doorn HR, Tan KY, Aalberse RC. Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites. Immunology 1999; 97:693 - 698
   PubMed Web of Science ®Google Scholar
• Schuurman J, Perdok GJ, Gorter AD, Aalberse RC. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 2001; 38:1 - 8
   PubMed Web of Science ®Google Scholar
• Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY. Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci 1997; 6:407 - 415
   Google Scholar
• Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993; 30:105 - 108
   PubMed Web of Science ®Google Scholar
• Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology 2002; 105:9 - 19
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767 - 771
   PubMed Web of Science ®Google Scholar
• Yoo EM, Wims LA, Chan LA, Morrison SL. Human IgG2 can form covalent dimers. J Immunol 2003; 170:3134 - 3138
   PubMed Web of Science ®Google Scholar
• Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen MJ, et al. Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem 2008; 283:16194 - 16205
   PubMed Web of Science ®Google Scholar
• Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008; 283:16206 - 16215
   PubMed Web of Science ®Google Scholar
• Duncan AR, Woof JM, Partridge LJ, Burton DR, Winter G. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 1988; 332:563 - 564
   PubMed Web of Science ®Google Scholar
• Ouellette D, Alessandri L, Chin A, Grinnell C, Tarcsa E, Radziejewski C, et al. Studies in serum support rapid formation of disulfide bond between unpaired cysteine residues in the V(H) domain of an immunoglobulin G1 molecule. Anal Biochem 2010; 397:37 - 47
   PubMed Web of Science ®Google Scholar
• Harris RJ. Heterogeneity of recombinant antibodies: linking structure to function. Dev Biol (Basel) 2005; 122:117 - 127
   PubMedGoogle Scholar
• Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005; 21:11 - 16
   PubMed Web of Science ®Google Scholar
• Howlett GJ, Minton AP, Rivas G. Analytical ultracentrifugation for the study of protein association and assembly. Curr Opin Chem Biol 2006; 10:430 - 436
   PubMed Web of Science ®Google Scholar
• Cole JL, Lary JW, T PM, Laue TM. Analytical ultracentrifugation: sedimentation velocity and sedimentation equilibrium. Methods Cell Biol 2008; 84:143 - 179
   PubMed Web of Science ®Google Scholar
• Kroe RR, Laue TM. NUTS and BOLTS: applications of fluorescence-detected sedimentation. Anal Biochem 2009; 390:1 - 13
   PubMed Web of Science ®Google Scholar
• Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol 2009; 20:708 - 714
   PubMed Web of Science ®Google Scholar
• Samaranayake H, Wirth T, Schenkwein D, Raty JK, Yla-Herttuala S. Challenges in monoclonal antibody-based therapies. Ann Med 2009; 41:322 - 331
   PubMed Web of Science ®Google Scholar
• Jones AJ, Papac DI, Chin EH, Keck R, Baughman SA, Lin YS, et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 2007; 17:529 - 540
   PubMed Web of Science ®Google Scholar
• Wawrzynczak EJ, Cumber AJ, Parnell GD, Jones PT, Winter G. Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains. Mol Immunol 1992; 29:213 - 220
   PubMedGoogle Scholar